UBS Group
TARO

UBS Group’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

UBS Group’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,317
Closed -$1.33M – 10333
2024
Q1 		$1.33M Sell
31,317
-5,587
-15% -$235K ﹤0.01% 4354
2023
Q4 		$1.54M Sell
36,904
-17,271
-32% -$637K ﹤0.01% 4086
2023
Q3 		$2.04M Buy
54,175
+19,588
+57% +$735K ﹤0.01% 3425
2023
Q2 		$1.31M Buy
34,587
+33,655
+3,611% +$1.06M ﹤0.01% 3979
2023
Q1 		$22.7K Buy
932
+381
+69% +$11.1K ﹤0.01% 6989
2022
Q4 		$16K Buy
551
+451
+451% +$13.4K ﹤0.01% 7931
2022
Q3 		$3K Sell
100
-825
-89% -$28.4K ﹤0.01% 9619
2022
Q2 		$34K Buy
925
+386
+72% +$14.7K ﹤0.01% 6279
2022
Q1 		$24K Sell
539
-236
-30% -$11K ﹤0.01% 7261
2021
Q4 		$39K Buy
775
+279
+56% +$15.6K ﹤0.01% 7162
2021
Q3 		$32K Sell
496
-4,135
-89% -$286K ﹤0.01% 6701
2021
Q2 		$333K Sell
4,631
-761
-14% -$55.9K ﹤0.01% 5014
2021
Q1 		$398K Sell
5,392
-383
-7% -$29.1K ﹤0.01% 5036
2020
Q4 		$424K Sell
5,775
-62,385
-92% -$4.01M ﹤0.01% 4725
2020
Q3 		$3.74M Buy
68,160
+21,655
+47% +$1.35M ﹤0.01% 2471
2020
Q2 		$3.09M Buy
46,505
+42,585
+1,086% +$2.86M ﹤0.01% 2468
2020
Q1 		$240K Buy
3,920
+1,350
+53% +$100K ﹤0.01% 4583
2019
Q4 		$226K Sell
2,570
-2,215
-46% -$187K ﹤0.01% 5530
2019
Q3 		$361K Sell
4,785
-7,803
-62% -$633K ﹤0.01% 4814
2019
Q2 		$1.08M Buy
12,588
+10,794
+602% +$1.07M ﹤0.01% 3703
2019
Q1 		$194K Buy
1,794
+203
+13% +$20.2K ﹤0.01% 4615
2018
Q4 		$135K Buy
1,591
+643
+68% +$62K ﹤0.01% 5282
2018
Q3 		$94K Sell
948
-970
-51% -$105K ﹤0.01% 5648
2018
Q2 		$222K Sell
1,918
-4,008
-68% -$440K ﹤0.01% 4866
2018
Q1 		$585K Sell
5,926
-276
-4% -$28K ﹤0.01% 4107
2017
Q4 		$650K Sell
6,202
-2,715
-30% -$298K ﹤0.01% 4102
2017
Q3 		$1M Buy
8,917
+1,953
+28% +$213K ﹤0.01% 3704
2017
Q2 		$780K Sell
6,964
-11,653
-63% -$1.32M ﹤0.01% 3807
2017
Q1 		$2.17M Sell
18,617
-2,259
-11% -$250K ﹤0.01% 2881
2016
Q4 		$2.2M Buy
20,876
+3,599
+21% +$377K ﹤0.01% 2840
2016
Q3 		$1.91M Buy
17,277
+10,048
+139% +$1.33M ﹤0.01% 2884
2016
Q2 		$1.05M Buy
7,229
+5,092
+238% +$722K ﹤0.01% 3336
2016
Q1 		$306K Sell
2,137
-6,676
-76% -$948K ﹤0.01% 4172
2015
Q4 		$1.36M Sell
8,813
-2,084
-19% -$304K ﹤0.01% 3153
2015
Q3 		$1.56M Buy
10,897
+4,086
+60% +$571K ﹤0.01% 2971
2015
Q2 		$979K Sell
6,811
-10,727
-61% -$1.53M ﹤0.01% 3587
2015
Q1 		$2.47M Buy
17,538
+9,643
+122% +$1.48M ﹤0.01% 2738
2014
Q4 		$1.17M Buy
+7,895
New +$1.16M ﹤0.01% 3441

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $3.3B AUM 20.27% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $2.24B AUM 23.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

UBS Group's TARO Position: Q2 2024 in Review

UBS Group sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 31,317 shares — an estimated $1.33M sold.

UBS Group first reported a position in TARO in Q4 2014 and held it in 38 quarters. The position peaked at $3.74M in Q3 2020. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • UBS Group reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • UBS Group sold 31,317 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $1.33M.
  • UBS Group first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2014 and held it in 38 quarters.
  • UBS Group's Taro Pharmaceutical Industries Ltd. position peaked at $3.74M in Q3 2020.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.